{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:02:25Z","timestamp":1790946145652,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.leukres.2022.106838","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T18:40:28Z","timestamp":1648320028000},"page":"106838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"116","author":[{"given":"Amira M.F.","family":"Shehata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy F.","family":"Gohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwa M.","family":"Muharram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar M. Kamal","family":"Eldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.leukres.2022.106838_bib1","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.3390\/ijms20246141","article-title":"Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update","volume":"20","author":"Bavaro","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.leukres.2022.106838_bib2","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.007","article-title":"Imatinib in chronic myeloid leukemia: an overview","volume":"6","author":"Sacha","year":"2014","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.leukres.2022.106838_bib3","article-title":"Therapy of chronic myeloid leukemia: twilight of the imatinib era?","volume":"2014","author":"Trela","year":"2014","journal-title":"ISRN Oncol."},{"key":"10.1016\/j.leukres.2022.106838_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Bixby","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"6","key":"10.1016\/j.leukres.2022.106838_bib5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2022.106838_bib6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","article-title":"Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents","volume":"25","author":"Talati","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.leukres.2022.106838_bib7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia","volume":"9","author":"Loscocco","year":"2019","journal-title":"Front Oncol."},{"issue":"26","key":"10.1016\/j.leukres.2022.106838_bib8","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.2174\/0929867321666140414101939","article-title":"Mechanism of cancer drug resistance and the involvement of noncoding RNAs","volume":"21","author":"Xia","year":"2014","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.leukres.2022.106838_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.3192","article-title":"The landscape of long noncoding RNAs in the human transcriptome","volume":"47","author":"Iyer","year":"2015","journal-title":"Nat. Genet"},{"issue":"1","key":"10.1016\/j.leukres.2022.106838_bib10","first-page":"81","article-title":"Tumor suppressor and oncogenic role of long non-coding RNAs in cancer","volume":"7","author":"Guzel","year":"2019","journal-title":"North Clin. Istanb."},{"key":"10.1016\/j.leukres.2022.106838_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7243968","article-title":"Long noncoding RNAs as biomarkers in cancer","volume":"2017","author":"Bolha","year":"2017","journal-title":"Dis. Markers"},{"issue":"17","key":"10.1016\/j.leukres.2022.106838_bib12","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.3748\/wjg.v25.i17.2029","article-title":"Recent advances in gastric cancer early diagnosis","volume":"25","author":"Necula","year":"2019","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.leukres.2022.106838_bib13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.gastro.2018.10.054","article-title":"Long Noncoding RNA GMAN, up-regulated in gastric cancer tissues, is associated with metastasis in patients and promotes translation of Ephrin A1 by competitively binding GMAN-AS","volume":"156","author":"Zhuo","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.leukres.2022.106838_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13059-018-1523-0","article-title":"A novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1","volume":"19","author":"Zhang","year":"2018","journal-title":"Genome Biol."},{"issue":"9","key":"10.1016\/j.leukres.2022.106838_bib15","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1101\/gr.152942.112","article-title":"CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer","volume":"23","author":"Ling","year":"2013","journal-title":"Genome Res"},{"key":"10.1016\/j.leukres.2022.106838_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108758","article-title":"Circulating long non-coding RNA colon cancer-associated transcript 2 protected by exosome as a potential biomarker for colorectal cancer","volume":"113","author":"Wang","year":"2019","journal-title":"Biomed. Pharm."},{"issue":"4","key":"10.1016\/j.leukres.2022.106838_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.23736\/S0026-4806.17.04703-6","article-title":"High expression of long non-coding RNA CCAT2 indicates poor prognosis of gastric cancer and promotes cell proliferation and invasion","volume":"108","author":"Wu","year":"2017","journal-title":"Minerva Med"},{"issue":"1","key":"10.1016\/j.leukres.2022.106838_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40659-017-0149-0","article-title":"CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma","volume":"51","author":"Cai","year":"2018","journal-title":"Biol. Res."},{"key":"10.1016\/j.leukres.2022.106838_bib19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.biopha.2016.12.122","article-title":"LncRNA CCAT2 promotes tumorigenesis by over-expressed Pokemon in non-small cell lung cancer","volume":"87","author":"Zhao","year":"2017","journal-title":"Biomed. Pharm."},{"issue":"7","key":"10.1016\/j.leukres.2022.106838_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317711314","article-title":"Long non-coding RNA CCAT2 promotes cell proliferation and invasion through regulating Wnt\/\u03b2-catenin signaling pathway in clear cell renal cell carcinoma","volume":"39","author":"Huang","year":"2017","journal-title":"Tumour Biol."},{"key":"10.1016\/j.leukres.2022.106838_bib21","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.biopha.2017.05.030","article-title":"Upregulation of CCAT2 promotes cell proliferation by repressing the P15 in breast cancer","volume":"91","author":"Deng","year":"2017","journal-title":"Biomed. Pharm."},{"issue":"1","key":"10.1016\/j.leukres.2022.106838_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13000-016-0499-x","article-title":"The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis","volume":"11","author":"Huang","year":"2016","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.leukres.2022.106838_bib23","series-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, Revised 4th Edition","first-page":"30","article-title":"Chronic myeloid leukaemia BCR-ABL1-positive","author":"Vardiman","year":"2017"},{"issue":"10","key":"10.1016\/j.leukres.2022.106838_bib24","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"6","key":"10.1016\/j.leukres.2022.106838_bib25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.leukres.2022.106838_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gene.2017.01.004","article-title":"Long noncoding RNA HULC promotes cell proliferation by regulating PI3K\/AKT signaling pathway in chronic myeloid leukemia","volume":"607","author":"Lu","year":"2017","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.leukres.2022.106838_bib27","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1002\/jcp.26119","article-title":"Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia","volume":"233","author":"Zhou","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"39","key":"10.1016\/j.leukres.2022.106838_bib28","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1038\/onc.2014.456","article-title":"Junk DNA and the long non-coding RNA twist in cancer genetics","volume":"34","author":"Ling","year":"2015","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.leukres.2022.106838_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Ther. Adv. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2022.106838_bib30","first-page":"1704","article-title":"LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p","volume":"7","author":"He","year":"2017","journal-title":"Am. J. Cancer Res"},{"issue":"1","key":"10.1016\/j.leukres.2022.106838_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/dna.2016.3533","article-title":"lncRNA UCA1 contributes to imatinib resistance by acting as a ceRNA Against miR-16 in chronic myeloid leukemia cells","volume":"36","author":"Xiao","year":"2017","journal-title":"DNA Cell Biol."},{"issue":"5","key":"10.1016\/j.leukres.2022.106838_bib32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4062\/biomolther.2016.162","article-title":"LncRNA MEG3 regulates imatinib resistance in chronic myeloid leukemia via suppressing MicroRNA-21","volume":"25","author":"Zhou","year":"2017","journal-title":"Biomol. Ther. (Seoul. )"},{"key":"10.1016\/j.leukres.2022.106838_bib33","first-page":"2657","article-title":"Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway","volume":"8","author":"Cai","year":"2015","journal-title":"Onco Targets Ther."},{"issue":"20","key":"10.1016\/j.leukres.2022.106838_bib34","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.8259","article-title":"shRNA targeting long non-coding RNA CCAT2 controlled by tetracycline-inducible system inhibits progression of bladder cancer cells","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.leukres.2022.106838_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317711314","article-title":"Long non-coding RNA CCAT2 promotes cell proliferation and invasion through regulating Wnt\/\u03b2-catenin signaling pathway in clear cell renal cell carcinoma","volume":"39","author":"Huang","year":"2017","journal-title":"Tumour Biol."},{"issue":"49","key":"10.1016\/j.leukres.2022.106838_bib36","doi-asserted-by":"crossref","first-page":"81806","DOI":"10.18632\/oncotarget.13242","article-title":"Knockdown of long non-coding RNA CCAT2 suppressed proliferation and migration of glioma cells","volume":"7","author":"Guo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2022.106838_bib37","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2147\/OTT.S127100","article-title":"Long non-coding RNA CCAT2 is associated with poor prognosis in hepatocellular carcinoma and promotes tumor metastasis by regulating Snail2-mediated epithelial\u2013mesenchymal transition","volume":"10","author":"Xu","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"4","key":"10.1016\/j.leukres.2022.106838_bib38","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.bbrc.2016.08.120","article-title":"The up-regulation of long non-coding RNA CCAT2 indicates a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition","volume":"480","author":"Zheng","year":"2016","journal-title":"Biochem Biophys. Res Commun."},{"issue":"6","key":"10.1016\/j.leukres.2022.106838_bib39","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1053\/j.gastro.2020.08.018","article-title":"The long noncoding RNA CCAT2 induces chromosomal instability through BOP1-AURKB Signaling","volume":"159","author":"Chen","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.leukres.2022.106838_bib40","first-page":"5658","article-title":"Upregulation of lncRNA CCAT2 predicts poor prognosis in patients with acute myeloid leukemia and is correlated with leukemic cell proliferation","volume":"11","author":"Li","year":"2018","journal-title":"Int J. Clin. Exp. Pathol."},{"issue":"9","key":"10.1016\/j.leukres.2022.106838_bib41","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00277-020-04161-9","article-title":"Long non-coding RNA CCAT2 as a potential serum biomarker for diagnosis and prognosis of multiple myeloma","volume":"99","author":"Xu","year":"2020","journal-title":"Ann. Hematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:01:53Z","timestamp":1758934913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":41,"alternative-id":["S0145212622000649"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106838","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106838"}}